Papers/PMID:23117245
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.
Annals of the rheumatic diseases2013The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
strontium(2+) — decreases WOMAC pain subscale
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Treatment with strontium ranelate 2 g/day was associated with significantly lower WOMAC total score (p=0.045) and pain subscore (p=0.028), and a trend toward lower physical function subscore (p=0.099) and global knee pain (p=0.065) (table 2).”
Quoted verbatim from Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.. - Study
- RCT
- Dose
- strontium ranelate 2 g/day
- Population
- Outpatients aged 50 or over with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3), intention-to-treat population; 2 g/day dose stratum only (the 1 g/day dose showed no significant reduction)
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.2013PMID:23117245Permalink